Sirolimus Albumin-Bound Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sirolimus Albumin-Bound Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sirolimus Albumin-Bound can convert its Non-degrading molecular glue profile and MUT x mTOR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sirolimus Albumin-Bound (query alias: Sirolimus Albumin-Bound) |
|---|---|
| Modality / target | Non-degrading molecular glue; MUT x mTOR; MUT stimulants, mTOR inhibitors, Immunosuppressants |
| Highest global status | Approved |
| Originator | Abraxis BioScience, Inc. |
| Active developers | Whitehawk Therapeutics, Inc., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd., Aadi Subsidiary, Inc. |
The MCP disease footprint includes Perivascular epithelioid cell tumour, Hormone receptor positive HER2 negative breast cancer, Epithelioid Hemangioendothelioma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| No matched detailed trial record returned. | ||||
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
FROM GENES TO REMISSION: PATHWAY-ALIGNED PRECISION THERAPY TRANSFORMS OUTCOMES IN CHILDREN WITH MONOGENIC IMMUNE DYSREGULATION DISEASES IN RESOURCE-LIMITED SETTINGS
Not Applicable; n=25; evaluation: Positive. Reported fields: CR = 55.6 %
EFFICACY AND SAFETY OF SIROLIMUS IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Phase 3; n=145; evaluation: Positive. Reported fields: SRI-4 = 22.7 % ; SRI-4 = 52.9 %
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Phase 2; n=39; evaluation: not stated. Reported fields: Biochemical Response = 0 Participants ; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sirolimus Albumin-Bound addresses Perivascular epithelioid cell tumour, Hormone receptor positive HER2 negative breast cancer, Epithelioid Hemangioendothelioma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Non-degrading molecular glue—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline | Phase 2 | US$3.8M stated total | |
| 2025-10-28 | Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements | Approved | Financial terms not disclosed |
| 2024-06-12 | Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland | Discovery | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
